Statins activate peroxisome proliferator-activated receptor γ through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages

Circulation Research

Volumn 100, Issue 10, 2007, Pages 1442-1451

  Yano, Miyuki ^a   Matsumura, Takeshi ^a,e   Senokuchi, Takafumi ^a   Ishii, Norio ^a   Murata, Yusuke ^a   Taketa, Kayo ^a   Motoshima, Hiroyuki ^a   Taguchi, Tetsuya ^a   Sonoda, Kazuhiro ^a   Kukidome, Daisuke ^a   Takuwa, Yoh ^b   Kawada, Teruo ^c   Brownlee, Michael ^d   Nishikawa, Takeshi ^a   Araki, Eiichi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Cyclooxygenase; Macrophages; MAPK; PPAR; Statins

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ABC TRANSPORTER A1; ATORVASTATIN; CD36 ANTIGEN; CERIVASTATIN; CYCLOOXYGENASE 2; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PITAVASTATIN; PROTEIN CDC42; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; MACROPHAGE ACTIVATION; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MONOCYTE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING;

ANIMALS; ANTIGENS, CD36; ATP-BINDING CASSETTE TRANSPORTERS; CDC42 GTP-BINDING PROTEIN; CELLS, CULTURED; CYCLOOXYGENASE 2; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FATTY ACIDS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICE, INBRED C3H; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PPAR ALPHA; PPAR GAMMA; PROSTAGLANDIN D2; SIGNAL TRANSDUCTION;

EID: 34249723258     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000268411.49545.9c     Document Type: Article

References (29)

1. Libby P, Aikawa M. New insights in plaque stabilization by lipid lowering. Nat Med. 2002;8:1257-1262.
2. Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering. Arterioscler Thromb Vasc Biol. 2001;21:3-5.
3. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719.
4. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298:1911-1912.
5. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol. 2006;38:1654-1661.
6. Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 and p38 mitogen-activated protein kinase pathways. J Biol Chem. 2000;275:14838-14845.
7. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 1995;83:813-819.
8. Francis GA, Annicotte JS, Auwerx J. PPAR agonists in the treatment of atherosclerosis. Curr Opin Pharmacol. 2003;3:186-191.
9. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000;106:523-531.
10. Grip O, Janciauskiene S, Lindgren S. Atorvastatin activates PPAR-γ and attenuates the inflammatory response in human monocytes. Inflamm Res. 2002;51:58-62.
11. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S. Modulation of inflammatory mediators and PPARγ and NFκB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res. 2002;45:147-154.
12. Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 1997;11:779-791.
13. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998;273:25573-25580.
14. Argmann CA, Edwards JY, Sawyez CG, O'Neil CH, Hegele RA, Pickering JG, Huff MW. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J Biol Chem. 2005;280:22212-22221.
15. Fajas L, Schoonjans K, Gelman L, Kim JB, Najib J, Martin G, Fruchart JC, Briggs M, Spiegelman BM, Auwerx J. Regulation of peroxisome proliferator- activated receptor γ expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol Cell Biol. 1999;19:5495-5503.
16. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J Clin Invest. 2001;107:1423-1432.
17. Casey PJ, Seabra MC. Protein prenyltransferases. J Biol Chem. 1996;271:5289-5292.
18. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ. Science. 1996;274:2100-2103.
19. Degraeve F, Bolla M, Blaie S, Creminon C, Quere I, Boquet P, Levy-Toledano S, Bertoglio J, Habib A. Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins. J Biol Chem. 2001;276:46849-46855.
20. Chen JC, Huang KC, Wingerd B, Wu WT, Lin WW. HMG-CoA reductase inhibitors induce COX-2 gene expression in murine macrophages: role of MAPK cascades and promoter elements for CREB and C/EBPβ. Exp Cell Res. 2004;301:305-319.
21. Birnbaum Y, Ye Y, Rosanio S, Tavackoli S, Hu ZY, Schwarz ER, Uretsky BF. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res. 2005;65:345-355.
22. Takano H, Nagai T, Asakawa M, Toyozaki T, Oka T, Komuro I, Saito T, Masuda Y. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-α expression in neonatal rat cardiac myocytes. Circ Res. 2000;87:596-602.
23. Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, Percevault F, Fruchart JC, Dombrowicz D, Glineur C, Staels B. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-α via inhibition of the protein kinase C signaling pathway. Circ Res. 2006;98:361-369.
24. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001;7:53-58.
25. Sato O, Kuriki C, Fukui Y, Motojima K. Dual promoter structure of mouse and human fatty acid translocase/CD36 genes and unique transcriptional activation by peroxisome proliferator-activated receptor α and γ ligands. J Biol Chem. 2002;277:15703-15711.
26. Senokuchi T, Matsumura T, Sakai M, Yano M, Taguchi T, Matsuo T, Sonoda K, Kukidome D, Imoto K, Nishikawa T, Kim-Mitsuyama S, Takuwa Y, Araki E. Statins suppress oxidized low-density lipoprotein-induced macrophage proliferation by inactivation of small G protein-p38 MAPK pathway. J Biol Chem. 2005;280:6627-6633.
27. Yano M, Matsumura T, Senokuchi T, Ishii N, Motoshima H, Taguchi T, Matsuo T, Sonoda K, Kukidome D, Sakai M, Kawada T, Nishikawa T, Araki E. Troglitazone inhibits oxidized low-density lipoprotein-induced macrophage proliferation: Impact of the suppression of nuclear translocation of ERK1/2. Atherosclerosis. 2007;191:22-32.
28. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357-362.
29. Paniagua JA, Lopez-Miranda J, Escribano A, Berral FJ, Marin C, Bravo D, Paz-Rojas E, Gomez P, Barcos M, Moreno JA, Perez-Jimenez F. Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes. Diabetes. 2002;51:2596-2603.